Neurocrine Biosciences (NBIX) Misses Q1 EPS by 114c; misses on guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $155.64 -1.71%
EPS Growth %: -12.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -12.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.51), $1.14 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $410 million versus the consensus estimate of $410.82 million.
GUIDANCE:
Neurocrine Biosciences sees FY2023 revenue of $1.67-1.77 billion, versus the consensus of $1.81 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
